

APPLERA CORP
Form 4
November 08, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
WINGER DENNIS L

(Last) (First) (Middle)

APPLERA CORPORATION, 301 MERRITT 7

(Street)

NORWALK, CT 06851-1070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
APPLERA CORP [ABI/CRA]

3. Date of Earliest Transaction
(Month/Day/Year)
11/06/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)

Senior Vice President and CFO

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Applied Biosystems Group Common Stock	11/06/2007		M		12,500	A	\$ 16,484
Applied Biosystems Group Common Stock	11/06/2007		S ⁽¹⁾		46	D	\$ 36.47
Applied Biosystems	11/06/2007		S ⁽¹⁾		137	D	\$ 36.42

Edgar Filing: APPLERA CORP - Form 4

Group Common Stock								
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	232	D	\$ 36.41	78,972.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	69	D	\$ 36.37	78,903.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	593	D	\$ 36.36	78,310.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	456	D	\$ 36.35	77,854.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	278	D	\$ 36.34	77,576.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	400	D	\$ 36.33	77,176.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	426	D	\$ 36.32	76,750.2555	D	
Applied Biosystems Group Common Stock	11/06/2007	<u>S⁽¹⁾</u>	428	D	\$ 36.31	76,322.2555	D	
Applied Biosystems Group	11/06/2007	<u>S⁽¹⁾</u>	306	D	\$ 36.3	76,016.2555	D	

Edgar Filing: APPLERA CORP - Form 4

Common Stock							
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	208	D	\$ 36.29	75,808.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	554	D	\$ 36.28	75,254.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	580	D	\$ 36.27	74,674.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	861	D	\$ 36.26	73,813.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	581	D	\$ 36.25	73,232.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	311	D	\$ 36.24	72,921.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	93	D	\$ 36.2	72,828.2555	D
Applied Biosystems Group Common Stock	11/06/2007	S ⁽¹⁾	140	D	\$ 36.19	72,688.2555	D
Applied Biosystems Group Common	11/06/2007	S ⁽¹⁾	44	D	\$ 36.18	72,644.2555	D

Edgar Filing: APPLERA CORP - Form 4

Stock							
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	46	D	\$ 36.15	72,598.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	114	D	\$ 36.1	72,484.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	94	D	\$ 36.09	72,390.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	162	D	\$ 36.04	72,228.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	277	D	\$ 36.02	71,951.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	624	D	\$ 36.01	71,327.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	1,216	D	\$ 36	70,111.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	761	D	\$ 35.99	69,350.2555	D
Applied Biosystems Group Common Stock	11/06/2007	<u>S(1)</u>	1,260	D	\$ 35.98	68,090.2555	D

Edgar Filing: APPLERA CORP - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 16.484	11/06/2007		M	12,500	03/30/2000 03/30/2008	Applied Biosystems Group Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WINGER DENNIS L APPLERA CORPORATION 301 MERRITT 7 NORWALK, CT 06851-1070			Senior Vice President and CFO	

Signatures

/s/ Thomas P. Livingston, Attorney-In-Fact for Dennis L. Winger 11/08/2007

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reflects sale by independent third-party administrator under the issuer's Insider Diversification Program.

Remarks:

Edgar Filing: APPLERA CORP - Form 4

This is the first of two forms being filed by the reporting person on November 8, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. /TD>

Triborough Bridge & Tunnel Auth. Rev.,
\$755

5.00%, 1/1/32, Ser. A

Aa2/AA- \$765,812 3,000

5.25%, 11/15/34, Ser. A-2 (e)

Aa2/AA- 3,157,110 2,945

Warren & Washington Cntys. Industrial Dev. Agcy. Rev., Glens Falls Hospital Project, 5.00%, 12/1/27, Ser. C
(AGM)

Aa3/AAA 3,024,191 400

Yonkers Industrial Dev. Agcy. Rev., Sarah Lawrence College Project, 6.00%, 6/1/41, Ser. A

NR/BBB+ 405,088

Total New York Municipal Bonds & Notes (cost \$115,966,935)
118,725,991

OTHER MUNICIPAL BONDS & NOTES 7.6%

California 1.1%

1,500

Los Angeles Department of Water & Power Rev., 5.00%, 7/1/39, Ser. A-1 (AMBAC)

Aa3/AA- 1,512,870

Louisiana 0.5%

750

Tobacco Settlement Financing Corp. Rev., 5.875%, 5/15/39, Ser. 2001-B

Baa3/BBB 701,865

Puerto Rico 5.7%

Aqueduct & Sewer Auth. Rev., Ser. A,

3,100

6.00%, 7/1/38

Baa3/BBB- 3,165,410 1,000

6.00%, 7/1/44

Baa3/BBB- 1,020,430

Sales Tax Financing Corp. Rev., Ser. A,

2,000

5.50%, 8/1/42 (a)

A2/A+ 1,988,000 1,500

Explanation of Responses:

5.75%, 8/1/37
A2/A+ 1,543,080

7,716,920

U.S. Virgin Islands 0.3%

500

Virgin Islands Public Finance Auth. Rev.

Baa2/BBB 450,815

Total Other Municipal Bonds & Notes (cost \$9,899,853)

10,382,470

OTHER VARIABLE RATE NOTES (b) 1.4%

Puerto Rico 1.4%

2,500

Commonwealth of Puerto Rico, Public Improvements, GO, 0.817%, 7/1/19, Ser. A (AGC) (cost \$2,137,020)

Aa3/AAA 1,917,250

SHORT-TERM INVESTMENTS 4.0% Corporate Notes (d) 2.2%

Financial Services 2.2%

2,900

American General Finance Corp., 4.625%, 9/1/10

B2/BB+ 2,833,248 200

International Lease Finance Corp., 0.482%, 5/24/10, FRN

B1/BB+ 196,066

Total Corporate Notes (cost \$2,620,514)

3,029,314

New York Variable Rate Demand Notes (b)(c) 1.8% 1,500

Syracuse Industrial Dev. Agcy. Rev., Syracuse Univ. Project, 0.15%, 2/1/10, Ser. A-2

VMIG1/A-1+ 1,500,000 1,000

Tompkins Cnty. Industrial Dev. Agcy. Rev., Cornell Univ., 0.21%, 2/1/10, Ser. A-1

VMIG1/A-1+ 1,000,000

Total New York Variable Rate Demand Notes (cost \$2,500,000)

Explanation of Responses:

2,500,000

Total Short-Term Investments (cost \$5,120,514)

5,529,314

Total Investments (cost \$133,124,322) **100.0%**

\$136,555,025

Notes to Schedule of Investments:

- * Portfolio securities and other financial instruments for which market quotations are readily available are stated at market value. Market value is generally determined on the basis of last reported sales prices, or if no sales are reported, based on quotes obtained from a quotation reporting system, established market makers, or independent pricing services.

Portfolio securities and other financial instruments for which market quotations are not readily available or for which a development/event occurs that may significantly impact the value of a security, are fair valued, in good faith, pursuant to procedures established by the Board of Trustees, or persons acting at their discretion pursuant to procedures established by the Board of Trustees. The Fund's investments are

valued daily using prices supplied by an independent pricing service or dealer quotations, or by using the last sale price on the exchange that is the primary market for such securities, or the mean between the last quoted bid and ask price for those securities which the over-the-counter market is the primary market or for listed securities in which there were no sales.

Independent pricing services use information provided by market makers or estimates of market values obtained from yield data relating to investments or securities with similar characteristics.

Securities purchased on a when-issued or delayed delivery basis are marked to market daily until settlement at the forward settlement value. Short-term securities maturing in 60 days or less are valued at amortized cost, if their original term to maturity was 60 days or less, or by amortizing their value on the 61st

day prior to maturity, if the original term to maturity exceeded 60 days.

The prices used by the Fund to value securities may differ from the value that would be realized if the securities were sold and these differences could be material. The Fund's net asset value is determined daily as of the close of regular trading (normally, 4:00 p.m. Eastern time) on the New York Stock Exchange (NYSE) on each day the NYSE is open for business.

- (a) Delayed-delivery.
To be settled/delivered after January 31, 2010.
- (b) Variable Rate Notes Instruments whose interest rates change on a specified date (such as a coupon date or interest payment date) and/or whose interest rates vary with changes in a designated base rate (such as the prime interest rate). The interest rate disclosed reflects the rate in effect on January 31, 2010.

- (c) Maturity date shown is date of next put.
- (d) All or partial amount segregated as collateral for reverse repurchase agreements.
- (e) Residual Interest Bonds held in Trust Securities represent underlying bonds transferred to a separate securitization trust established in a tender option bond transaction in which the Fund acquired the residual interest certificates. These securities serve as collateral in a financing transaction.

Glossary:

AGC insured by Assured Guaranty Corp.
 AGM insured by Assured Guaranty Municipal Corp.
 AMBAC insured by American Municipal Bond Assurance Corp.
 FGIC insured by Financial Guaranty Insurance Co.
 FHA insured by Federal Housing Administration
 FRN Floating Rate Note. The interest rate disclosed reflects the rate in effect on January 31, 2010.
 GO General Obligation Bond
 NPFGC insured by National Public Finance Guarantee Corp.
 NR Not Rated
 WR Withdrawn Rating

Other Investments:

Open reverse repurchase agreements at January 31, 2010:

Counterparty	Rate	Trade Date	Maturity Date	Principal & Interest	Principal
Barclays Bank	0.75%	1/6/10	2/9/10	\$ 2,708,410	\$ 2,707,000

Edgar Filing: APPLERA CORP - Form 4

The weighted average daily balance of reverse repurchase agreements outstanding during the nine months ended January 31, 2010 was \$3,706,188 at a weighted average interest rate of 0.75%. The total market value of underlying collateral (refer to the Schedule of Investments for positions segregated as collateral for reverse repurchase agreements) for open reverse repurchase agreements at January 31, 2010 was \$3,029,314. The Fund received \$156,387 in principal value of U.S. government agency securities as collateral for reverse repurchase agreements outstanding. Collateral received as securities cannot be pledged.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the exit price) in an orderly transaction between market participants. The three levels of the fair value hierarchy are described below:

Level 1 quoted prices in active markets for identical investments that the Fund has the ability to access

Level 2 valuations based on other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.) or quotes from inactive exchanges

Level 3 valuations based on significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

An investment asset's or liability's level within the fair value hierarchy is based on the lowest level input, individually or in the aggregate, that is significant to fair value measurement. The objective of fair value measurement remains the same even when there is a significant decrease in the volume and level of activity for an asset or liability and regardless of the valuation technique used.

The valuation techniques used by the Fund to measure fair value during the nine months ended January 31, 2010 maximized the use of observable inputs and minimized the use of unobservable inputs.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

A summary of the inputs used at January 31, 2010 in valuing the Fund's assets and liabilities is listed below:

	Level 1 - Quoted Prices	Level 2 - Other Significant Observable Inputs	Level 3 - Significant Unobservable Inputs	Value at 1/31/10
Investments in Securities Assets				
Municipal Bonds & Notes		\$ 118,725,991		\$ 118,725,991
Other Municipal Bonds & Notes		10,382,470		10,382,470
Other Variable Rate Notes		1,917,250		1,917,250
Short-Term Investments		5,529,314		5,529,314
Total Investments		\$ 136,555,025		\$ 136,555,025

In January 2010, the Financial Accounting Standards Board released ASU 2010-06, Improving Disclosures About Fair Value Measurements. ASU 2010-06 is effective for annual and interim reporting periods beginning after December 15, 2009. At this time the Fund management is in the process of reviewing ASU 2010-06 to determine future applicability.

Item 2. Controls and Procedures

(a) The registrant's President & Chief Executive Officer and Treasurer, Principal Financial & Accounting Officer have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Act (17 CFR 270.30a-3(c))), are effective based on their evaluation of these controls and procedures as of a date within 90 days of the filing date of this document.

(b) There were no significant changes in the registrant's internal controls over financial reporting (as defined in Rule 30a-3(d) under the Act (17 CFR 270.30a-3(d))) that occurred during the registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3. Exhibits

(a) Exhibit 99.302 Cert. Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant: PIMCO New York Municipal Income Fund

By /s/ Brian S. Shlissel

President & Chief Executive Officer

Date: March 22, 2010

By /s/ Lawrence G. Altadonna

Treasurer, Principal Financial & Accounting Officer

Date: March 22, 2010

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By /s/ Brian S. Shlissel

President & Chief Executive Officer

Date: March 22, 2010

By /s/ Lawrence G. Altadonna

Treasurer, Principal Financial & Accounting Officer

Date: March 22, 2010